DCN Dx and Mapp Biopharmaceutical Announce Subcontract

Addressing the Need for the Rapid Non-subjective, Digitized Detection of Ebola and Ebola Family Viruses CARLSBAD, Calif., Feb. 1, 2023 /PRNewswire/ — DCN Dx, a global leader in the end-to-end development, manufacturing, and commercialization of point-of-use tests, today announced a…

Click here to view original post